Side-by-side comparison of AI visibility scores, market position, and capabilities
Chicago global brewer (NYSE: TAP) ~$11.7B FY2024 revenue; Coors Light/Miller Lite Bud Light boycott beneficiaries, Coors Banquet cultural renaissance, premiumization competing with ABI and Constellation.
Molson Coors Beverage Company is a Chicago, Illinois-based global brewer and beverage company — publicly traded on the New York Stock Exchange (NYSE: TAP) as an S&P 500 Consumer Staples component — brewing and selling beer and flavored beverages through iconic brands including Coors Light, Miller Lite, Coors Banquet, Blue Moon, Molson Canadian, Carling, and hard seltzers through approximately 17,000 employees in over 30 countries. In fiscal year 2024, Molson Coors reported net sales of approximately $11.7 billion with underlying pretax income growth driven by premiumization mix shift and cost management, as the company continued executing its Revitalization Plan to grow net sales per hectoliter through premium brand investment and above-premium portfolio expansion. CEO Gavin Hattersley's strategy capitalized on the 2023 Bud Light controversy — Anheuser-Busch InBev's Dylan Mulvaney partnership backlash triggered a historic consumer boycott that shifted an estimated 2-3 share points of mainstream US beer volume from Bud Light to Coors Light and Miller Lite in 2023-2024 — representing the largest beer market share shift in decades, as Molson Coors brands became the beneficiary of Bud Light's largest-ever US sales decline. Molson Coors accelerated above-premium brand investment (Peroni Nastro Azzurro, Blue Moon LightSky, Simply Hard Lemonade partnership with Coca-Cola) to capture volume shift at higher margin price points while the two mainstream brands (Coors Light and Miller Lite) absorbed the incremental mainstream volume from Bud Light share loss.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.